Valeo Pharma Inc represents a values-driven corporate philosophy centered on innovation, integrity, and patients' well-being. As a pharmaceutical company, Valeo Pharma prioritizes product quality and safety, striving to provide effective healthcare solutions. With a focus on patient care, Valeo Pharma aims to improve the lives of individuals by developing and commercializing innovative pharmaceutical products. Through its dedication to research and development, the company demonstrates a commitment to advancing healthcare technologies and addressing unmet medical needs. Valeo Pharma's corporate philosophy encompasses responsibility, transparency, and collaboration, enabling them to deliver trusted and impactful healthcare solutions to enhance patient outcomes.

Valeo Pharma Inc is primarily present in Canada.

Valeo Pharma Inc has achieved several significant milestones. Firstly, the company successfully obtained Health Canada approval for many of its innovative pharmaceutical products, allowing them to be commercially available in the Canadian market. Additionally, Valeo Pharma Inc has established partnerships and collaborations with renowned pharmaceutical companies, facilitating the expansion of their product offerings and market reach. The company has also demonstrated strong financial performance, displaying consistent revenue growth and profitability. Furthermore, Valeo Pharma Inc has made continuous efforts to enhance its portfolio by acquiring promising pharmaceutical assets and actively pursuing research and development initiatives.

Valeo Pharma Inc is a pharmaceutical company with a rich history and background. Founded in 2003, Valeo Pharma has become a leading player in the Canadian healthcare industry. The company focuses on the development, licensing, and distribution of innovative prescription and over-the-counter (OTC) pharmaceutical products. Valeo Pharma is committed to providing high-quality medicines and improving patient outcomes. With a strong management team and strategic partnerships, the company has experienced significant growth and expansion. Valeo Pharma's dedication to innovation, excellence, and patient care has made it a trusted name in the pharmaceutical sector.

The main competitors of Valeo Pharma Inc in the market include various pharmaceutical companies such as Pfizer, GlaxoSmithKline, Novartis, and Johnson & Johnson.

Valeo Pharma Inc is primarily active in the healthcare and pharmaceutical industries.

The business model of Valeo Pharma Inc revolves around the development, acquisition, and commercialization of innovative pharmaceutical products. As a specialty pharmaceutical company, Valeo Pharma focuses on providing unique therapeutic solutions to meet unmet medical needs. They collaborate with global pharmaceutical companies to establish partnerships and licensing agreements for bringing novel products to the Canadian market. Valeo Pharma's strategic approach combines in-house product development, leveraging its regulatory and clinical expertise, with a strong emphasis on product acquisition and commercialization. By continuously expanding its portfolio and reaching partnerships, Valeo Pharma aims to deliver innovative healthcare solutions to patients in Canada.

Valeo Pharma KGV ir -0,18.

Valeo Pharma KUV ir 0,08.

AlleAktien kvalitātes vērtējums Valeo Pharma ir 4/10.

gaidāmā Valeo Pharma apgrozījums ir 58,68 milj. CAD.

gaidāmā Valeo Pharma peļņa ir -26,91 milj. CAD.

Valeo Pharma Inc. is a Canadian pharmaceutical company based in Quebec that specializes in the development, manufacturing, and marketing of products in various therapy areas. The company aims to provide innovative solutions for unmet medical needs and is committed to improving the health and well-being of patients. The company is divided into four main business segments: Valeo Pharma Canada, Valeo Pharma International, Valeo Distribution, and Valeo Health. Valeo Pharma Canada is the core business of the company and focuses on marketing prescription drugs and consumer products, including pain and inflammation medications, cardiovascular and renal drugs, antidepressants, antipsychotics, and vitamins. The company markets several innovative products and has established strong relationships with key players in the Canadian healthcare industry. Valeo Pharma International is the international division of the company, specializing in expanding into new markets outside of Canada. The company leverages its deep knowledge of the global pharmaceutical and medical markets to build successful business relationships and market innovative products worldwide. Valeo Distribution is the distribution arm of the company, focusing on distributing the products of Valeo Pharma Canada and Valeo Pharma International. The company works closely with physicians, pharmacies, and health authorities to ensure effective distribution of the products. It also provides logistics and distribution services for other partner companies. Valeo Health is the company's newest business segment, specializing in the development of wellness and lifestyle products. The company has developed a unique line of products aimed at improving consumer well-being and health, and enhancing their quality of life. This includes weight management products, dietary supplements, and skincare products. Overall, Valeo Pharma Inc. has a broad portfolio of products that enables it to operate at various levels of the healthcare industry. The company is committed to improving healthcare in Canada and beyond by developing and marketing innovative products that help patients achieve their health goals. With strong leadership and a dedicated team, Valeo Pharma Inc. is well positioned to grow in the pharmaceutical industry and create value for its customers and shareholders.

Valeo Pharma izmaksā dividendes 0 CAD, kas tiek izmaksātas reizes gadā.

Dividendes pašlaik nevar aprēķināt Valeo Pharma vai uzņēmums nedod dividendes.

Valeo Pharma ISIN ir CA91915B1085.

Valeo Pharma WKN ir A2PLB4.

Valeo Pharma simbols ir VPH.TO.

Pēdējo 12 mēnešu laikā Valeo Pharma maksāja dividendes apmērā. Tas atbilst aptuveni dividendes ražībai. Nākamajos 12 mēnešos Valeo Pharma plāno maksāt dividendes 0 CAD apmērā.

Valeo Pharma pašreizējā dividendu rentabilitāte ir .

Valeo Pharma maksā dividendes ceturksnī. Tās tiek izmaksātas mēnešos .

Valeo Pharma pēdējo 0 gadu laikā katru gadu izmaksāja dividendes.

Nākamajiem 12 mēnešiem tiek prognozētas dividendes apmērā 0 CAD. Tas atbilst dividendes ražībai 0 %.

Valeo Pharma tiek piešķirts nozarei "—".

Lai saņemtu pēdējo dividendu Valeo Pharma apmērā 0 CAD, kas tika izmaksāta 12.09.2024., tev akcija bija jāpatur depozītā līdz Ekss dienai, kas bija 12.09.2024..

Pēdējās dividendes izmaksa notika 12.09.2024..

Gadā 2023, Valeo Pharma izmaksāja 0 CAD dividendes.

Valeo Pharma dividendes tiek izmaksātas CAD.